Glucagon-like Peptide-1-Based Therapies Do Not Interfere With Blood Glucose Monitoring Systems.

Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JKM is a member in the advisory boards of Abbott Diabetes Care, Becton-Dickinson/Embecta, Biomea, Eli Lilly, Medtronic, Novo Nordisk, Pharmasens, Roche Diabetes Care, Sanofi, and Viatris; received speaker honoraria from Abbott Diabetes Care, A. Menarini Diagnostics, Becton-Dickinson/Embecta, Dexcom, Eli Lilly, MedTrust, Novo Nordisk, Roche Diabetes Care, Sanofi, and Ypsomed; and is a shareholder of decide Clinical Software GmbH and elyte Diagnostics. BH, RS, GB, and JR are the employees of Roche Diabetes Care GmbH and Roche Diabetes Inc.